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For patients with non-small-cell lung cancer (NSCLC), surgical
resection offers the best chance for long-term survival. However,
approximately two-thirds of NSCLC patients have unresectable
disease. Although radiotherapy has played an important role in the
treatment of locally advanced unresectable NSCLC, the treatment
outcome for such patients has remained poor due to both locore-
gional and systemic failures (median survival time (MST), 9.1
months; 2-year survival rate, 13.5%) (Gould et al, 1995). To
improve this disappointing situation, many approaches have been
tried, including a modified fractionation method for radiation (Cox
et al, 1990; Saunders et al, 1996), combined chemoradiotherapy
(Le Chevalier et al, 1991; Blanke et al, 1995; Furuse et al, 1995;
Jeremic et al, 1995, 1996; Sause et al, 1995; Dillman et al, 1996;
Lee et al, 1996), and preoperative chemoradiotherapy (Weiden
et al, 1991; Strauss et al, 1992; Albain et al, 1995; Choi et al, 1997;
Eberhardt et al, 1998). Among these modalities of treatment,
survival advantage has been demonstrated for patients receiving
combined chemoradiotherapy (Jeremic et al, 1995, 1996; Sause
et al, 1995; Dillman et al, 1996). In a meta-analysis of 22 random-
ized clinical trials (chemoradiotherapy vs radiotherapy alone),
chemoradiotherapy resulted in a 10% reduction in the annual risk
of death and a consequent improvement in 2-year survival from
15% to 18% (Non-small Cell Lung Cancer Collaborative Group,
1995). In addition, cisplatin-based chemotherapy yielded better
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Summary A recent meta-analysis and randomized studies have demonstrated that combined chemoradiotherapy is associated with a
survival advantage for selected patients with locally advanced unresectable non-small-cell lung cancer (NSCLC). We conducted a phase II
study of combined chemoradiotherapy to find a more effective combination of drugs and radiation than those previously reported for such
patients. Between January 1994 and November 1996, 50 previously untreated patients with locally advanced unresectable NSCLC (stage IIIA
with N2 or IIIB disease) were entered in this study. Patients were required to have Eastern Cooperative Oncology Group performance status
≤ 2, age ≤ 75 years and adequate organ function. Treatment consisted of three cycles of cisplatin (20 mg m–2, days 1–5) and 5-fluorouracil
(5-FU) (500 mg m–2, days 1–5) every 4 weeks, and concurrent hyperfractionated thoracic radiation (1.25 Gy twice daily, with a 6-h interfraction
interval; total radiation dose, 62.5–70 Gy). Of the 50 patients entered, 37 (74%) responded to this chemoradiotherapy, including two (4%) with
complete response. By a median follow-up time of 41.0 months, 35 patients had died and 15 were still alive. The median time to progression
for responding patients was 14.1 months (range, 2.6–51.3+ months). The median survival time was 18.7 months, with a survival rate of 66.0%
at 1 year, 46.0% at 2 years and 27.6% at 3 years. Survival outcome was strongly affected by the extent of nodal involvement (median survival
time, 27.4 months for N0–2 disease (n = 37) vs 10.7 months for N3 disease (n = 13); P = 0.007). The major toxicities of treatment were
leukopenia and neutropenia (³ Grade 3, 58% and 60% respectively). Other toxicities of ³ Grade 3 included thrombocytopenia (26%), anaemia
(26%), nausea/vomiting (16%) and radiation oesophagitis (6%). Treatment-related death occurred for one patient. Our findings suggest that
cisplatin and 5-FU in combination with concurrent hyperfractionated thoracic radiation is effective and feasible for the treatment of locally
advanced unresectable NSCLC. The short-term survival in this study appeared to be more encouraging than those of similar chemoradiation
trials. A randomized trial will be needed to compare the combination of cisplatin and 5-FU with other platinum-based regimens together with
concurrent hyperfractionated thoracic radiation. In addition, in future studies, inclusion criteria for N3 disease with or without supraclavicular
involvement should be reconsidered to correctly evaluate the effect of combined chemoradiotherapy for locally advanced unresectable
NSCLC. © 2000 Cancer Research Campaign
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results than those obtained with other drugs and their combina-
tions (Non-small Cell Lung Cancer Collaborative Group, 1995).
In this study, we employed a combination of cisplatin and
5-fluorouracil (5-FU) demonstrated to have synergistic anti-
tumour activity in both preclinical (Scanlon et al, 1986; Esaki et al,
1992) and clinical studies (Rooney et al, 1985; Kemeny et al,
1990). For lung cancer, this combination yielded a response rate
ranging from 25% to 47% (Lynch et al, 1994; Gemma et al, 1995;
Tsuchiya et al, 1995), although 5-FU alone is thought to be
inactive against NSCLC (response rate, 8.1%) (Citron et al, 1992).
The mechanism of synergism between these two drugs remains
unclear. However, there are various hypotheses concerning the
modulatory effect of cisplatin on 5-FU, and vice versa; concerning
the former, it has been suggested that cisplatin-induced increase of
reduced intracellular folate level potentiates the effect of
5-fluorodeoxyuridine monophosphate by forming a covalent
ternary complex with thymidylate synthase, leading to enhanced
5-FU cytotoxicity (Scanlon et al, 1986), while concerning the
latter, it has been suggested that modulation of cisplatin-induced
DNA-adduct repair by 5-FU results in enhanced cisplatin cyto-
toxicity (Esaki et al, 1992).
Hyperfractionated radiation therapy is expected to increase anti-
tumour effects and decrease toxicity to normal tissues (Cox et al,
1990; Roach et al, 1995; Segawa et al, 1997). In a published series,
patients receiving hyperfractionated radiation therapy appeared to
have a better prognosis than those treated with conventional radio-
therapy (Sause et al, 1995; Bonner et al, 1998). Considering the
radiosensitizing effects of cisplatin and 5-FU (Vokes et al, 1990), it
appears possible that concurrent combination of hyperfractionated
radiation therapy with these drugs will increase their antitumour
effect by increasing the frequency of interaction between
chemotherapy and radiotherapy.
Based on this background, the Okayama Lung Cancer Study
Group conducted a prospective phase II study to evaluate the
efficacy and toxicity of a combination of cisplatin and 5-FU
combined with concurrent hyperfractionated thoracic radiation for
locally advanced unresectable NSCLC.
PATIENTS AND METHODS
Eligibility criteria
This phase II study was designed to treat locally advanced, surgi-
cally unresectable NSCLC. Based on the TNM staging system
adopted in 1986 (Mountain, 1986), patients with stage IIIA with
N2 or IIIB disease were eligible for inclusion in this study. Patients
with malignant pleural or pericardial effusion, or with pleural
dissemination were excluded. Patients were required to have a
histologically or cytologically confirmed diagnosis of NSCLC,
previously untreated disease, measurable lesions, Eastern
Cooperative Oncology Group (ECOG) performance status (PS)
≤ 2, age ≤ 75 years and no history of malignancy within 5 years
before enrolment. Any patients who had previously undergone
chemotherapy or radiotherapy were excluded from this study.
Before enrolment, each patient gave a complete medical
history and underwent physical, laboratory and staging work-up
examinations. Laboratory examinations included complete blood
cell counts, serum chemistry and tumour marker analyses, 24-h
creatinine clearance evaluation, arterial blood gas analysis,
urinalysis, electrocardiogram and pulmonary function tests.
Staging work-up examination consisted of chest plain radiographs,
computerized tomography (CT) of the chest and abdomen
(ultrasonography of the abdomen could be substituted), magnetic
resonance imaging of the brain, radionucleotide bone scan and
fibreoptic bronchoscopy. Mediastinoscopy was not included in the
staging work-up examination. On laboratory examination, patients
were required to have a white blood cell (WBC) count ³ 4000 ml–1,
platelet (PLT) count ³ 100 000 ml–1, haemoglobin level ³ 9g  d l –1,
serum bilirubin level ≤ 1.5 mg dl–1, serum AST and ALT levels
≤ 2.5 times the upper limit of normal, 24-h creatinine clearance
level ³ 60 ml min–1 and arterial oxygen pressure ³ 60 mmHg.
Patients with markedly diminished pulmonary function status
(i.e. ≤ 50% of the predicted vital capacity and/or ≤ 40% forced
expiratory volume in 1 s of the predicted value), and those with
serious complications such as unstable angina, congestive heart
failure, uncontrolled diabetes mellitus, or severe obstructive
pneumonia were excluded from this study.
Written informed consent was obtained from all patients. Four
institutions participated in this study, and their Institutional
Review Boards approved this study. The patients were entered in
this study after verification of eligibility by the central registration
office (Second Department of Internal Medicine, Okayama
University Medical School).
Chemotherapy
Eligible patients received three cycles of chemotherapy consisting
of cisplatin (20 mg m–2, days 1–5) and 5-FU (500 mg m–2, days
1–5) every 4 weeks. Cisplatin was intravenously administered for
30 min, followed by 2-h infusion of 5-FU. Before and after
cisplatin instillation, all patients received 2000–2500 ml infusion
over 4 h. In the second and third cycles of chemotherapy, dose
modification was performed based on the haematological toxici-
ties observed in the prior cycle of chemotherapy. Modified doses
of cisplatin and 5-FU were as follows: 24 mg m–2 and 600 mg m–2
at dose level +1, 16 mg m–2 and 400 mg m–2 at dose level –1, and
14 mg m–2 and 300 mg m–2 at dose level –2. The two drugs were
administered at dose level +1 when leukopenia or neutropenia
remained at ≤ Grade 2, without thrombocytopenia; they were
administered at dose level –1 when Grade 4 leukopenia or
neutropenia, or Grade 3 or higher thrombocytopenia developed;
they were administered at dose level –2 when severe infection or
bleeding tendency associated with haematological toxicity was
observed. In case of acceptable toxicities other than those
mentioned above, chemotherapy was repeated at the starting dose.
In addition, at the time of the next cycle of chemotherapy, the
drugs were administered at dose level –1 when WBC and PLT
counts were 3000–3900 ml–1 and 75 000–99 000 ml–1 respectively.
Chemotherapy was not given until haematological recovery when
WBC and PLT counts were less than 3000 ml–1 and 75 000 ml–1
respectively. The cisplatin dose was reduced by half when 24-h
creatinine clearance level decreased below 60 ml min–1 but was
³ 30 ml min–1. Neither drug was given when 24-h creatinine
clearance level was less than 30 ml min–1.
All patients received prophylactic antiemetic therapy using
5-hydroxytryptamine type 3 receptor blocker and/or dexametha-
sone. When Grade 3 or higher leukopenia or neutropenia occurred,
recombinant human granulocyte colony stimulating factor
(rhG-CSF) administration was permitted under the guidelines of
the Japanese Ministry of Health and Welfare.106 Y Segawa et al
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Radiotherapy
Radiotherapy was started on day 1 of chemotherapy, using a linear
accelerator (6–10 MeV). The radiation dose was 2.5 Gy with two
fractions per day (1.25 Gy per fraction) with a 6-h interfraction
interval. A total dose of 62.5–70 Gy was delivered in 10 fractions
per week for 5 consecutive days. The treatment volumes consisted
of original and boost volumes. The initial dose of 45 Gy was
administered to the original volume, which included the site of
primary tumour with a margin of 2 cm around the mass and the
ipsilateral hilum, and the whole width of the mediastinum with a
margin of 1 cm around the radiographically visible region of
involvement extending inferiorly to 3 cm below the carina or 2 cm
below the radiographically-demonstrated tumour mass. The supra-
clavicular region was further included if involved with tumour. An
additional 17.5–25 Gy was administered to the boost volume that
included the site of primary tumour and involved lymph nodes.
The original volume was treated with an anterior-posterior
parallel-opposed pair of portals, and the boost volume was treated
with the same pair or with a pair of oblique fields if cumulative
radiation dose to the spinal cord was over 45 Gy.
When Grade 3 or higher radiation oesophagitis toxicity
occurred, radiation therapy was withheld until radiation
oesophagitis recovered to ≤ Grade 2. On the other hand, in case of
Grade 3 or higher leukopenia or neutropenia, radiation therapy
was not discontinued.
Response and toxicity evaluation
For evaluation of response and toxicity, all patients treated on an
inpatient basis underwent a series of examinations consisting of
complete blood cell counts, serum chemistry and plain chest
radiographs on at least a weekly basis during the treatment period
and then on a monthly basis. CT scans of the chest were performed
after each cycle of chemotherapy, and the same examinations as
for the staging work-up study were performed after completion of
the treatment.
Responses were assessed using the World Health Organization
(WHO) criteria (Miller et al, 1981). The response to treatment,
including eligibility and assessibility, was determined for each
patient by extramural reviewers. Complete response (CR) was
defined as the disappearance of all measurable lesions for at least
4 weeks. Partial response (PR) was defined as a ³ 50% decrease in
the sum of the products of the greatest perpendicular diameters of
all measurable lesions for at least 4 weeks without the develop-
ment of new lesions. Progressive disease (PD) was defined as a
³ 25% increase in the sum of the products of the perpendicular
diameters of all measurable disease or the appearance of new
lesions. If no response or progression of disease occurred during
therapy, treatment outcome was considered no change (NC).
Toxicities were assessed using the WHO criteria (Miller et al,
1981), and grading of acute oesophageal toxicity due to radiation
was evaluated in accordance with that of oral toxicity.
Statistical analysis
The sample size of this study was determined on the assumption
that the expected response rate was 75%, with a 95% confidence
interval (CI) of ± 12.5%.
Statistical analyses were performed using the SPSS Base
System™ and Advanced Statistics™ programs (SPSS Inc,
Chicago, IL, USA). For comparison of proportions for categorical
variables, the c2 test was used. Survival time was defined as the
period from the initiation of treatment to death or last follow-up
evaluation. In addition, time to progression was defined as the
period from the initiation of treatment to PD. Survival curves were
calculated using the method of Kaplan and Meier, and differences
in survival distribution between two categorized groups were
assessed using a log-rank test. To estimate the prognostic signifi-
cance of covariates for survival, a Cox regression model was
employed in backward step-wise fashion. P-values less than 0.05
in two-tailed analyses were considered significant.
RESULTS
Patient characteristics
Between January 1994 and November 1996, 50 patients were
entered in this study, and all were included for analyses of
response, survival and toxicity. Patient characteristics are shown in
Table 1. There were 45 males and five females, with a median age
of 63 years (range 38–74 years). Forty-seven (94%) patients had a
good ECOG PS of 0–1, and 17 (34%) had weight loss ³ 10%
during the 6-month period preceding the study entry. Twenty-two
(44%) patients had squamous cell carcinoma, 20 (40%) adeno-
carcinoma, six (12%) large cell carcinoma, and one (2%) each
adenosquamous cell carcinoma and unclassified carcinoma.
Thirteen (26%) patients had stage IIIA and 37 (74%) stage IIIB
Table 1 Patient characteristics
Characteristic No. of patients
No. of patients entered 50
No. of patients eligible 50
Median age in years (range) 63 (38–74)
Gender
Male 45
Female 5
ECOG performance status
01 7
13 0
23
Weight loss
< 10% 33
³ 10% 17
Histology
Squamous cell carcinoma 22
Adenocarcinoma 20
Large-cell carcinoma 6
Adenosquamous cell carcinoma 1
Unclassified carcinoma 1
Stage of diseasea
IIIA 13
IIIB 37
TNM classificationa
T4N0M0 6
T4N1M0 1
T1N2M0 4
T2N2M0 4
T3N2M0 5
T4N2M0 17
T2N3M0 6
T3N3M0 3
T4N3M0 4
a TNM staging system adopted in 1986.Concurrent chemoradiation for NSCLC 107
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disease. The mediastinum, heart, great vessels, trachea, oesoph-
agus, or vertebral body was involved in 28 (56%) patients. Based
on the extent of nodal involvement, six (12%) patients had N0, one
(2%) N1, 30 (60%) N2 and 13 (26%) N3 disease. Of patients with
N3 disease, four (8%) had unilateral or bilateral metastasis to
supraclavicular lymph nodes.
Treatment accomplishment
Thirty-three (66%) patients completed three cycles of
chemotherapy, with dose elevation for two (4%) and reduction for
11 (22%) patients. The second and third cycles of chemotherapy
were not administered to six (12%) and 17 (34%) patients respec-
tively. Reasons for not completing chemotherapy were patient
refusal (n = 5), toxicity or death (n = 5), physician’s discretion 
(n = 4) and disease progression (n = 3). Cases of discontinuation
at physician’s discretion included deterioration of PS for two
patients, and cerebral infarction and massive haemoptysis
requiring bronchial arterial embolization in one case each.
Treatment-related death occurred for one patient, due to dissemi-
nated intravascular coagulation syndrome caused by infection
associated with severe neutropenia. The median interval between
the first and second cycles of chemotherapy was 32.5 days (range
21–70 days), while that between the second and third cycles was
35 days (25–51 days). The actuarial dose intensities of
chemotherapy (administered dose per time unit/projected dose per
time unit; mean ± standard deviation (s.d.) were 73.6 ± 16.3% for
cisplatin and 73.4 ± 16.8% for 5-FU.
Forty-seven (94%) patients completed radiotherapy; however,
six (12%) of the patients required a rest period from radiation
(median, 15.5 days; range 11–43 days), due to radiation
oesophagitis (n = 3), deterioration of PS (n = 2), or fever of
unknown origin (n = 1). Total radiation dose and duration (mean ±
s.d.) were 68.5 ± 3.9 Gy and 43.6 ± 6.2 days respectively. In addi-
tion, of the 47 patients who completed radiotherapy, ten received a
total radiation dose of 62.5–67.5 Gy while 37 received 70 Gy. Of
44 patients who received the second cycle of chemotherapy,
38 (76%) received it during the period of radiotherapy. Overall,
33 (66%) of the 50 patients completed both chemotherapy and
radiotherapy with no or minor modification of dose or schedule. In
addition, two (4%) patients who had a good response after the
completion of this therapy underwent surgery, although this study
was not intended to include an adjuvant surgery setting. Pathologic
CR was confirmed in one of these patients, and both were still
alive without recurrence of disease at the last follow-up evaluation
(24.6 and 51.3 months respectively).
Response
Responses to the combined chemoradiotherapy are summarized in
Table 2. Of the 50 patients entered, two (4%) had CR, 35 (70%)
PR, eight (16%) NC and three (6%) PD. The remaining two (4%)
patients were suspended from response evaluation due to treat-
ment-related death and cerebral infarction in one case each.
Therefore, the overall response rate was 74%, with a 95% CI of
61.8–86.2%. There were no differences in response rate by age
(≤ 63 vs > 63 years, P = 0.747), gender (P = 0.162), ECOG PS
(0 to 1 vs 2, P = 0.290), weight loss (< 10% vs ³ 10%, P = 0.775),
or T factor group (T0–3 vs T4, P = 0.856). However, patients with
N0–2 disease responded significantly better than those with N3
disease (83.8% vs 46.2%; P = 0.008). The difference in response
rate was even more striking on comparison with a subgroup of
Table 2 Response rate and survival by pretreatment factors
No. of
Response
Response MST
Variable patients CR PR NC PD NE rate (%) P-value (months) P-value
Overall 50 2 35 8 3 2 74.0 18.7
Age
≤ 63 years 25 2 16 3 3 1 72.0 24.0
> 63 years 25 0 19 5 0 1 76.0 0.747 18.6 0.998
Gender
Male 45 2 30 8 3 2 71.1 23.8
Female 5 0 5 0 0 0 100.0 0.162 17.7 0.854
ECOG performance status
0–1 47 2 32 8 3 2 72.3 24.0
2 3 0 3 0 0 0 100.0 0.290 10.5 0.080
Weight loss
< 10% 33 2 22 6 2 1 72.7 27.2
³ 10% 17 0 13 2 1 1 76.5 0.775 16.5 0.254
Histology
Adenocarcinoma 20 0 12 5 2 1 60.0 18.6
Non-adenocarcinoma 30 2 23 3 1 1 83.3 0.065 18.7 0.308
Stage of diseasea
IIIA 13 0 12 1 0 0 92.3 32.7
IIIB 37 2 23 7 3 2 67.6 0.080 16.5 0.186
T factora
0–3 22 0 16 3 2 1 72.7 24.0
4 28 2 19 5 1 1 75.0 0.856 17.7 0.838
N factora
0–2 37 2 29 5 0 1 83.8 27.4
3 13 0 6 3 3 1 46.2 0.008 10.7 0.007
a TNM staging system adopted in 1986. MST, median survival time; NE, not evaluable.108 Y Segawa et al
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patients with supraclavicular lymph node metastasis (n = 4)
(83.8% vs 0%, P < 0.001). In addition, non-adenocarcinoma
patients and those with stage IIIA disease tended to respond better
than those with adenocarcinoma (P = 0.065) and those with stage
IIIB disease (P = 0.080) respectively. There were no significant
differences in response rate between the other histological groups
(e.g. 81.8% for squamous cell carcinoma vs 67.6% for non-
squamous cell carcinoma, P = 0.264).
By a median follow-up time of 41.0 months (range 24.2–53.2
months), 25 of the 37 responding patients had relapsed. The
median time to progression for the responding patients was 14.1
months (range 2.6–51.3+ months). Excluding the two patients
suspended from response evaluation, the most common site of
initial failure was local (n = 24, 50%) and the second most
common site was brain (n = 6, 12.5%) (Table 3). The local
progression-free survival rate was 57.1% at 1 year, 45.2% at
2 years and 42.0% at 3 years, with a median of 17.0 months
(Figure 1). In addition, the distant progression-free survival rate
was 64.4% at 1 year, 52.9% at 2 years and 49.1% at 3 years, with a
median of 25.7 months (Figure 1).
Survival
The survival curve for the 50 patients is shown in Figure 2. By a
median follow-up time of 41.0 months, 35 (70%) patients had died
and 15 (30%) were still alive. The cause of death was directly
related to NSCLC for 33 patients and unrelated for two (treatment-
related death and pulmonary infarction in one case each). The
survival rate was 66.0% at 1 year, 46.0% at 2 years and 27.6%
at 3 years, with an MST of 18.7 months. There were no differences
in survival by age (≤ 63 vs > 63 years, P = 0.998), gender
(P = 0.854), weight loss (< 10% vs ³ 10%, P = 0.254), histology
(adenocarcinoma vs non-adenocarcinoma, P = 0.308), disease
stage (IIIA vs IIIB, P = 0.186), or T factor group (T0–3 vs T4,
P = 0.838) (Table 2). However, patients with N0–2 disease had
significantly better survival than those with N3 disease (MST, 27.4
vs 10.7 months, P = 0.007). Similar to the findings for response
rates, the difference in survival was strongly significant on
comparison with the subgroup of patients with supraclavicular
lymph node metastasis (MST, 27.4 vs 2.1 months, P < 0.001). In
addition, patients with a good ECOG PS of 0–1 tended to have
better survival than those with PS of 2 (MST, 24.0 vs 10.5 months,
P = 0.080).
Factors influencing survival were further assessed using a Cox
regression model. All of the parameters listed in Table 2 were
included and analysed in backward step-wise fashion. The finally
selected model (c2 (1) = 7.381, P = 0.007) demonstrated that N
factor was a dominant prognostic factor in our series of NSCLC
patients (hazard ratio, 2.653; 95% CI 1.278–5.505; P = 0.009).
Toxicity
Toxicities observed in the 50 patients during treatment and the
follow-up period are listed in Table 4. The major toxicity was
myelosuppression. Grade 3 or higher leukopenia and neutropenia
occurred in 29 (58%) and 30 (60%) patients respectively. In addi-
tion, Grade 3 or higher thrombocytopenia and anaemia occurred in
13 (26%) patients each. rhG-CSF was administered following
35 (28.7%) of the 122 assessable cycles of chemotherapy, for
a median duration of 6 days (range 2–24 days). In addition, 15
patients underwent rhG-CSF administration during radiotherapy
while 35 did not. Grade 3 or higher thrombocytopenia was
observed in four of the former 15 patients (PLT nadir counts:
17 000, 21 000, 40 000 and 44 000 ml–1), with a median duration of
4 days (range 3–12 days), although ³ Grade 3 thrombocytopenia
was observed in none of the remaining 35 patients. Non-haemato-
logic toxicities were generally mild, although Grade 3 or higher
radiation eosophagitis occurred in three (6%) patients. No Grade 3
or higher radiation pneumonitis was observed in this study.
Overall,  ³ Grade 3 toxicity was observed in 37 (74%) patients;
34 (68%) of them experienced haematological toxicity alone,
Table 3 Pattern of initial failure
Initial recurrence No. of patients %
No. of patients evaluateda 48
No. of patients failed 34 70.8
Local progression only 20 41.7
Distant progression only 10 20.8
Brain (+ liver) 6 (1)
Bone 2
Adrenal 1
Skin 1
Local + distant progression 4 8.3
Retroperitoneal lymph node 2
Cervical lymph node 1
Liver 1
a Two patients who were suspended from response evaluation were excluded
from this analysis.
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while nine (18%) of them experienced only nonhaematologic
toxicity.
DISCUSSION
Combined chemoradiotherapy is now accepted as a standard form
of therapy for locally advanced unresectable NSCLC, based on
results of both a recent meta-analysis (Non-small Cell Lung
Cancer Collaborative Group, 1995) and large-scaled randomized
trials (Sause et al, 1995; Dillman et al, 1996) that compared
combined chemoradiotherapy with radiotherapy alone.
Accordingly, the interest of many investigators is focused on the
timing and mode of radiotherapy, and on the selection and combi-
nation of drugs for patients with this condition. Although possible
advantage of concurrent combination of chemotherapy and radio-
therapy over sequential combination was suggested in a West
Japan Lung Cancer Group trial (Furuse et al, 1997), definitive
conclusions have not been obtained concerning this issue,
including whether fractionated radiation methods such as standard
fractionation or hyperfractionation are useful. In this study, the
effectiveness and feasibility of cisplatin and 5-FU in combination
with concurrent hyperfractionated thoracic radiation were evalu-
ated to find a promising concurrent chemoradiotherapy regimen
for locally advanced unresectable NSCLC.
Regarding treatment outcome in this study, 66% of the patients
completed both chemotherapy and radiotherapy with no or only
minor modification of the treatment schedule. The overall
response rate and MST were 74% and 18.7 months respectively. In
addition, both locoregional and distant progression-free survivals
were fairly good (median values, 17.0 and 25.7 months respec-
tively). The major toxicities were leukopenia and neutropenia, for
which  rhG-CSF was administered following 28.7% of the
chemotherapy cycles. Although rhG-CSF was administered to
30% of the patients during radiotherapy following the first cycle of
chemotherapy, life-threatening thrombocytopenia was a rare event
within the period of radiotherapy. The incidences of Grade 3 or
higher radiation oesophagitis and pneumonitis were quite low (6%
and 0% respectively), in contrast to those in a series of concurrent
chemoradiotherapy trials (12–53% and 1–25% respectively) (Lee
et al, 1996; Blanke et al, 1997; Choy et al, 1998; Jeremic et al,
1998; Clamon et al, 1999). Additionally, although this study used
different boost dose settings (17.5–25 Gy), no significant differ-
ences were found in response rate, survival, or toxicity profile
between the different boost dose groups (data not shown).
Results of concurrent chemoradiotherapy trials in a published
series and our own are listed in Table 5. For a phase III series,
Jeremic et al (1995, 1996) reported significantly favourable
survival in each arm consisting of weekly or daily
carboplatin/etoposide combined with hyperfractionated thoracic
radiation compared with this type of radiotherapy-alone arm. In a
trial reported by Clamon et al (1999), 10% lower local recurrence
rate was demonstrated for induction chemotherapy followed by
concurrent chemoradiotherapy arm than for the sequential
chemoradiotherapy arm, but this improvement did not lead to a
survival advantage. Interestingly, Bonner et al (1998) found a
possible survival advantage for hyperfractionated radiation
therapy over standard radiotherapy in a subset analysis of their
study. In a phase II series, several platinum-based chemotherapy
regimens were concurrently combined with standard or hyperfrac-
tionated thoracic radiotherapy with differing dose settings for radi-
ation. Among these, Jeremic et al (1998) and Choy et al (1998)
reported promising treatment results in terms of MST (25 and 20.5
months respectively). In addition, the 2-year and 3-year survival
rates (46.0% and 27.6% respectively) in our trial were among the
most encouraging obtained.
However, our findings should be carefully interpreted due to the
small sample size and non-randomized setting. In general, treat-
ment outcome is strongly affected by the clinical background of
patients enroled. This study included only a few patients with poor
PS, but included some ineligible patients with weight loss ³ 10%
and those with N3 disease. Patients with N3 disease in this study
had extremely poor survival compared with those with N0–2
disease (MST, 10.7 vs 27.4 months), although the diagnosis of N3
disease was made based mainly on chest CT imaging, with a
criterion of short-axis diameter of lymph node ³ 1 cm. This differ-
ence in survival was even more striking when compared with the
survival of the subgroup of patients with supraclavicular lymph
node metastasis (MST, 2.1 vs 27.4 months). Given the large
proportion of patients with weight loss, a well-known indicator of
poor prognosis for NSCLC (Paesmans et al, 1995), this study does
Table 4 Haematological and non-haematological toxicities
No. of patients with toxicities
% of toxicities
Toxicity Grade 1 Grade 2 Grade 3 Grade 4 ³ Grade 3
Leukopenia 3 18 22 7 58
Neutropenia 8 11 18 12 60
Thrombocytopenia 5 10 5 8 26
Anaemia 7 18 10 3 26
Nausea/vomiting 20 13 8 0 16
Diarrhoea 6 0 1 0 2
Fever 8 7 0 0 0
Alopecia 24 10 0 0 0
Renal dysfunction 3 2 0 0 0
Liver dysfunction 3 1 0 0 0
Peripheral neurotoxicity 2 0 0 0 0
Oesophagitis 22 6 1 2 6
Pneumonitis 13 4 0 0 0
Worst haematological toxicity per patient 2 14 18 16 68
Worst non-haematological toxicity per patient 12 26 7 2 18
Worst toxicity per patient 1 12 20 17 74110 Y Segawa et al
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not appear to have a strong bias in patient selection yielding falsely
positive treatment outcome.
Trials of preoperative chemotherapy and radiotherapy for stage
IIIA with N2 and/or IIIB disease reported MSTs ranging from 13
to 25 months (Weiden et al, 1991; Strauss et al, 1992; Albain et al,
1995; Choi et al, 1997; Eberhardt et al, 1998). Among these, Choi
et al (1997) and Eberhardt et al (1998) have recently reported
promising long-term survival with the use of concurrent
chemotherapy and hyperfractionated radiation therapy. It is
difficult to compare treatment outcomes between trials including
and not including surgery because of their differences in patient
eligibility. However, these results also indicate the effectiveness of
concurrent chemotherapy and hyperfractionated radiation therapy
for locally advanced unresectable NSCLC.
In the present study, we employed a combination of cisplatin
and 5-FU. However, only a few findings are available concerning
which types of drugs are well tolerated and provide synergistic
effects with radiotherapy. It will thus be necessary to find effective
drugs and their combinations, including new drugs such as taxans
and topoisomerase I inhibitors.
In conclusion, a combination of cisplatin and 5-FU together
with concurrent hyperfractionated thoracic radiation was found to
be effective and feasible for the treatment of locally advanced
unresectable NSCLC. A randomized trial will be needed to
compare a combination of cisplatin and 5-FU with other platinum-
based regimens together with concurrent hyperfractionated
thoracic radiation. In addition, in future studies, inclusion criteria
for N3 disease with or without supraclavicular involvement should
be reconsidered to correctly evaluate the effect of combined
chemoradiotherapy for locally advanced unresectable NSCLC.
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